- Home
- CLVT vs NRIX Comparison
CLVT vs NRIX Comparison
Compare CLVT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLVT | NRIX |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United Kingdom | United States |
| Employees | 12000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLVT | NRIX |
|---|---|---|
| Price | $2.04 | $17.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $3.22 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 4.8M | 2.5M |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $1.66 | $8.20 |
| 52 Week High | $4.77 | $22.50 |
Technical Indicators
Market Signals| Indicator | CLVT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 59.72 |
| Support Level | $1.66 | $17.21 |
| Resistance Level | $2.72 | $19.98 |
| Average True Range (ATR) | 0.15 | 1.34 |
| MACD | -0.04 | 0.15 |
| Stochastic Oscillator | 11.25 | 70.88 |
Price Performance
Historical ComparisonAbout CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.